RxDoctor Payments Data

Rene Garcia, MD

Family Medicine · Miami, FLNPI 1316986995

Payments from drug & device makers

$4,022in general payments, 2019–2025

Across 79 payments — averaging $50.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$926
  • Lilly USA, LLC$336
  • Novartis$237
  • Pfizer$193
  • Boehringer Ingelheim$178
  • plus $788 from 10 others

What the payments were for

  • Food & beverage$3,99299%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,022 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$17,736
Medicare patients
72
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$66,494
ProliaDenosumab28$47,735
JanuviaSitagliptin Phosphate28$31,164
Breo ElliptaFluticasone/Vilanterol76$30,370
SynthroidLevothyroxine Sodium271$24,594
FarxigaDapagliflozin Propanediol17$17,715
MyrbetriqMirabegron22$14,603
TradjentaLinagliptin18$13,965
Omeprazole700$12,333
TrulicityDulaglutide13$11,710
JardianceEmpagliflozin14$10,572
Repatha SureclickEvolocumab12$10,113
XareltoRivaroxaban16$9,856
LivaloPitavastatin Calcium17$9,164
Atorvastatin Calcium1,142$7,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$193$68,82091 claims
AmgenProlia$926$47,73528 claims
GSKBreo Ellipta$143$30,37076 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,364$27,63539 claims
AbbVieSynthroid$173$24,594271 claims
Boehringer IngelheimTradjenta, Jardiance$178$24,53732 claims
Astellas Pharma US IncMyrbetriq$66$14,60322 claims
Lilly USA, LLCTrulicity$336$11,71013 claims
Johnson & JohnsonXarelto$35$9,85616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →